DESIGN AND CHARACTERIZATION OF SUSTAINED RELEASE MATRIX TABLETS OF METFORMIN HYDROCHLORIDE USING COMBINATION OF HYDROPHILIC POLYMERS
Sustained release system is types of modified drug delivery system that can be used as an alternative to conventional system. Among different dosage forms, matrix tablets are widely accepted for oral sustained release Metformin hydrochloride has relatively short plasma half-life, low absolute bioavailability. The need for the administration two to three times a day when larger doses are required can decrease patient compliance. Sustained release formulation that would maintain plasma level for 8-12 h might be sufficient for daily dosing of metformin. Sustained release products are needed for metformin to prolong its duration of action and to improve patient compliances. They are capable of reducing the dose intake, minimize the blood level oscillation dose related adverse effect and cost thus improves the patient compliance in the therapeutic management of diabetes. The Metformin hydrochloride matrix Sustained release tablets were prepared using different hydrophilic polymers in various proportions as release retarding agent to prolong the drug release and to improve the patience compliance. The tablets were evaluated for various tests like hardness, friability, disintegration and in-vitro dissolution studies.
Keywords: Matrix Tablets, Metformin hydrochloride, Hardness, Friability, Disintegration and in-vitro dissolution studies
2. Wiley A. Insulin and oral hypoglycemic drugs. In: Williams DA, Lemke TL, editors. Foyes Principle of medicinal chemistry. New York: Lippincott Williams and Wilkins; 2002. pp. 641â€“8.
3. Martindale SC. London: The Pharmaceutical Press; 2002. The Complete Drug Reference.
4. Dunn CJ, Peters DH, Metformin A review of its pharmacological properties and therapeutic use in non-insulindependent diabetes mellitus Drugs, 1995, 49, 5, 721-749.
5. Dunn CJ, Peters DH. Metformin: A review of its pharmacological properties and therapeutic use in noninsulin-dependent diabetes mellitus. Drugs. 1995; 49:721â€“49. [PubMed: 7601013]
6. Defang O, Shufang N, Wei L. In vitro and in vivo evaluation of two extended Release preparations of combination metformin and glipizide. Drug Dev Ind Pharm. 2005; 31:677â€“85. [PubMed: 16207615]
7. Salsa T, Veiga F, Pina ME. Oral control release dosge form I. Cellulose ether polymer in hydrophilic matrices. Drug Dev Ind Pharm. 1997; 23:929â€“38.
8. Chien YW. New York: Marcel Dekker; 1992. Novel drug delivery systems; pp. 1â€“43.
9. Mehta KA, Kislaloglu MS, Phuapradit W, Malik AW, Shah NH. Release performance of a poorly soluble drug from a novel Eudragit-based multiunite erosion matrix. Int J Pharm Sci. 2001; 213:7â€“12.
10. Kibbe AH. Washington DC: American Pharmaceutical Association; 2000. Handbook of pharmaceutical excipients.
11. Sanchez L, Teresa F, Fernandez A, Alvarez F, Rabasco A, Mura P. Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers. Int J Pharm Sci. 2002; 234:213â€“21.
12. Reddy KR, Mutalik S, Reddy S. Once-daily sustained-release matrix tablets of Nicorandil: Formulation and in vitro evaluation. AAPS PharmSciTech. 2003; 61:4. [PMCID: PMC2750654]
13. Rodriguez L, Caputo O, Cini M, Cavallari C, Grecchi R. In vitro release of theophylline from directly compressed matrices containing methacrylic acid copolymers and/or dicalcium posphate dihydrate. II Farmaco. 1993; 48:1597â€“604.
14. Rao VM, Engh K, Qiu Y. Design of pH-independent controlled release matrix tablets for acidic drugs. Int J Pharm Sci. 2003; 252:81â€“6.
15. Gohel MC, Patel TP, Bariya SH. Studies in preparation and evaluation of pH independent sustained release matrix tablets of verapamil HCl using directly compressible Eudragits. Pharm Dev Technol. 2003; 8:323â€“33. [PubMed: 14601957]
16. Liu J, Zhang F, McGinity JW. Properties of lipophilic matrix tablets containing phenylpropanolamine hydrochloride prepared by hot-melt extrusion. Eur J Pharm Biopharm. 2001; 52:181â€“90. [PubMed: 11522484] release. Pharm Dev Technol. 1997; 2:161â€“70. [PubMed: 9552442]
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).